Midatech Pharma Plc (MTP)’s Financial Results Comparing With BioXcel Therapeutics Inc. (NASDAQ:BTAI)

We will be comparing the differences between Midatech Pharma Plc (NASDAQ:MTP) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) as far as profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Midatech Pharma Plc N/A 0.00 N/A -0.85 0.00
BioXcel Therapeutics Inc. N/A 0.00 22.19M -1.33 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Midatech Pharma Plc and BioXcel Therapeutics Inc.


Table 2 demonstrates the net margins, return on assets and return on equity of Midatech Pharma Plc and BioXcel Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Midatech Pharma Plc 0.00% 0% 0%
BioXcel Therapeutics Inc. 0.00% -53.2% -48.5%

Insider and Institutional Ownership

The shares of both Midatech Pharma Plc and BioXcel Therapeutics Inc. are owned by institutional investors at 0% and 20.9% respectively. Insiders held roughly 32.1% of Midatech Pharma Plc’s shares. Comparatively, 1.1% are BioXcel Therapeutics Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Midatech Pharma Plc -21.05% -30.38% 48.92% -56.58% -79.38% 6.45%
BioXcel Therapeutics Inc. -8.91% 5.4% 4.27% 82.03% 13.05% 178.24%

For the past year Midatech Pharma Plc has weaker performance than BioXcel Therapeutics Inc.


On 4 of the 6 factors Midatech Pharma Plc beats BioXcel Therapeutics Inc.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.